Table 2.
Relationship between CLL1 target copy number and potency of CLL1-ADC in various AML cells lines
| Cell line | Anti-CLL1 antibody/isotype control antibody MFI ratio | Relative copy no. | CLL1-ADC IC50, ng/mL |
|---|---|---|---|
| EOL-1 | 10.0 | 35 740 | 1.4 |
| HEL92.1.7 | 1.6 | 5 575 | >>5000 |
| HL60 | 17.7 | 66 000 | 1.7 |
| Nomo-1 | 3.7 | 13 045 | 328 |
| OCI-AML2 | 17.1 | 61 220 | 0.6 |
| OCI-AML5 | 16.6 | 63 000 | 0.7 |
| OCI-M1 | 1.2 | 4 180 | 1535 |
| PL21 | 11.2 | 39 920 | 27.0 |
| TF-1 | 1.3 | 4 570 | >5000 |
| TF-1/CLL1 | 8.6 | 30 560 | 1.8 |
| U937 | 2.8 | 9 830 | 384 |
Relative MFI is determined by CLL1 antibody staining fluorescent intensity divided by IgG control antibody staining fluorescent intensity. CLL1 target copy number in various AML cell lines is estimated using FACS-based assay with standard markers. IC50 of toxicity on cells is determined by incubation of various concentrations of CLL1-ADC with AML cells.